Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vitamin E

This article was originally published in The Tan Sheet

Executive Summary

Three-year study finding "vitamin E supplement intake above 450 IU per day may block early atherosclerotic progression" pointed to by CRN to dispute contrary research in recent Journal of the American Medical Association article. Conducted by James Dwyer, PhD, University of Southern California, et al., and presented at a recent AHA conference, the CRN-cited study hypothesizes that other research on vitamin E and coronary heart disease may have failed to detect benefits due to insufficient dosing and intervention at later disease stages. Conversely, Emma Meagher, MD, University of Pennsylvania, et al., failed "to detect any impact of vitamin E on three quantitative indices of lipid peroxidation" in the March 7 JAMA study. Pennsylvania group's conclusions "were based on short-term markers of a biochemical process, not clinically significant disease markers" such as "the build-up of plaque in the arteries," CRN maintains

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts